RadMD managed imaging for a phase II trial for Ipsen biopharmaceuticals’ new Gallium PET imaging agent to assess somatostatin receptor (SSTR2) positive gastroenteropancreatic neuroendocrine tumor (GEP-NET) that employed novel independent read methodology.
RadMD selected, trained and managed readers and independent reads and provide expert consultancy for read preparation (site training, site qualification, charter writing etc) Three expert radiologists assessed CT data and 3 expert nuclear physicians assessed PET data. The results were presented at the Society of Nuclear Medicine and Molecular Imaging Meeting held in July 2020.